Iron chelation therapy in patients with low- to intermediate-risk myelodysplastic syndrome: A systematic review and meta-analysis

Br J Haematol. 2022 Apr;197(1):e9-e11. doi: 10.1111/bjh.17998. Epub 2021 Dec 19.

Authors

Sarah Yang¹, Ming Chan Zhang², Russell Leong³, Lawrence Mbuagbaw⁴, Mark Crowther⁵, Allen Li^{1

5}

Affiliations

¹ Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
² Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
³ Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
⁴ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
⁵ Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 34927248
DOI: 10.1111/bjh.17998

No abstract available

Keywords: iron chelation therapy; iron overload; myelodysplastic syndrome; overall survival; randomised controlled trials.

Publication types

Letter
Meta-Analysis
Systematic Review

MeSH terms

Chelation Therapy
Humans
Iron / therapeutic use
Iron Chelating Agents / therapeutic use
Iron Overload* / drug therapy
Iron Overload* / etiology
Myelodysplastic Syndromes* / drug therapy

Substances

Iron Chelating Agents
Iron